However, EGFR mutation was found to be generally rare in most malignancies except lung cancers, and gefitinib-sensitive cancers without EGFR mutations have been reported in HER2-overexpressing breast cancer cell lines as representative examples (Moasser et al, 2001; Moulder et al, 2001). This evidence concerns the gene ERBB2 and breast carcinoma.